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ess: pinarcelik@yahoo.cSummary This study aims to investigate the possibility of additional value of
leukotriene receptor antagonist (LTA) on dyspnea score, arterial blood gases (ABG),
pulmonary function tests (PFTs), and quality of life (St. George QoL) in chronic
obstructive pulmonary disease (COPD) patients. In this randomized, prospective,
single-blind, and controlled study, 117 non-reversible COPD patients defined by
global initiative for chronic obstructive lung disease (GOLD) criteria were
randomized to receive ipratropium bromide, formoterol and montelukast (n:58,
montelukast group) or ipratropium bromide and formoterol (n:59, control group)
after a 2-week run-in period. There was no significant demographic difference
between the two groups (P40:05). Baseline ABG, PFT, visual analoque scores (VAS),
and QoL scores were obtained and at first month and second month, PFT, VAS, and
QoL scores were repeated and ABG was obtained at second month and the values
were compared with baseline values. As the result of the comparision, there was
significant increase in vital capacity, FVC, FEV1, VAS, and PaO2 parameters (Po0:05),
and a significant decrease in the QoL scores (Po0:05) in the montelukast group.
These parameters did not show any difference in the control group (P40:05).
Sputum samples that could be obtained in 24 of the COPD patients were evaluated
and in the montelukast group, there was a decrease in neutrophilic activity after
treatment (n:13) (P :0:059). These results suggest that LTA that is used additionally in
routine treatment protocol can produce additive improvement on PFT, dyspnea score
and especially QoL in patients with stable COPD and for these reasons, LTA may be
taken into account when there is need for an additional anti-inflammatory treatment
in COPD patients.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is
characterized by progressive development of air-
flow limitation that is not fully reversible.1 COPD
has been increasingly recognized as an inflamma-
tory disease characterized by sputum neutrophilia
and, in some cases, eosinophilia. Patients with
COPD classically have neutrophilic bronchial in-
flammation and increased airway concentration of
the neutrophil chemoattractant leukotrienes. Neu-
trophil recruitment to the airway is thought to be
an important component of the ongoing inflamma-
tion and progression of chronic obstructive pul-
monary disease. Increased numbers of neutrophils
are found in bronchial lavage samples and bronchial
biopsy specimens from subjects with COPD even
when they are clinically stable. There is evidence
that the decline in forced expiratory volume in the
first second (FEV1) is related with airway neutro-
philia.2 Therefore, the fact that neutrophil en-
zymes can cause all the pathological features of
COPD, it has long been thought that neutrophils
play a central role in the pathogenesis and
progression of COPD.
Leukotriene B4 (LTB4) and interleukine 8 (IL-8)
are both potent chemoattractants capable of
promoting neutrophil transendothelial migration,
and increased levels of these two chemoattractants
have been found in secretions from patients with
COPD, particularly those with severe stages.3,4 LTB4
is a proinflammatory derivative of arachidonic acid.
It upregulates the neutrophil adhesion molecule,
and is both a potent neutrophil chemoattractant
and a neutrophil activator.5 Cysteinyl leukotrienes
(LTC4, LTD4 ve LTE4) are known to induce mucus
secretion, inflammatory cell infiltration, increase
vascular permeability and tissue edema, damage
ciliary clirens, and cause severe bronchoconstric-
tion. In spite of many studies with LTAs in asthma,
there have been very few studies about their anti-
inflammatory use in COPD.
We have performed a randomized, prospective,
single-blind, controlled trial to assess the effects of
leukotriene receptor antagonist (LTA), montelukast,
on health-related quality of life (QoL), pulmonary
function test (PFT), dyspnea score, arterial blood
gas (ABG), and sputum neutrophil content.Methods
One hundred and seventeen stable COPD patients
defined by the global initiative for chronic obstruc-
tive lung disease (GOLD)1 criteria were recruited inour outpatient respiratory department between
December 2002 and July 2003. Inclusion criteria at
entry were chronic airflow impairment (percentage
of FEV1o80% and FEV1/FVCo70%), clinically stable
condition with no exacerbation for 6 weeks prior to
assessment, non-reversible airway obstruction,
non-atopic patients and clinically stable co-mor-
bidity. The patients who had a change less than 12%
or absolute 200ml in FEV1 after 400 mg salbutamol
inhalation were accepted as having non-reversible
airway obstruction.1 Patients were randomized to
receive ipratropium bromide (4 40 mg), formote-
rol (2 12 mg) and montelukast (10mg every night)
(n:58) or ipratropium bromide and formoterol
(n:59) following the 2-week run-in period. During
run-in period, all patients were prescribed to use
the same drugs, ipratropium bromide and formo-
terol to standardize the treatment. Salbutamol
inhaler was used as rescue medication. The first
patient who had the inclusion criteria had been
randomized by throwing a coin and the following
patients had treatment consecutively.
Age, smoking status, exacerbations in the last
year, duration of COPD, co-morbidity, and physical
examination findings were noted.
After run-in period, baseline ABG, PFT, visual
analoque scores (VAS), health-related QoL called
St. George’s Respiratory Questionnaire (SGRQ)7
which include symptom score, activity score,
impact score and total score, and sputum samples
were obtained. At the first and the second month of
the study, PFTs, VAS, and health-related QoL scores
were measured. ABG and sputum samples were
obtained at the second month.
Pulmonary function tests
PFT were done with Jaeger Master Screen Pneumo
Device (Jaeger Co, Hoechberg, Germany) by the
same technician every time. Spirometric para-
meters, FEV1, forced vital capacity (FVC), vital
capacity (VC), FEV1/FVC, and peak expiratuar flow
(PEF) were measured.
Dyspnea score assessment
VAS was used for assessment of dyspnea level.
Patients were asked for marking the line that is
100mm according to feeling of dyspnea. 100mm
was defined as dyspnea always present.6
Quality of life measurement
QoL was assessed using Turkish translation of
SGRQ, 50-item disease-specific questionnaire that
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scores in three areas: symptom, activity, and
impact of disease on daily life. To calculate, the
total and subscale scores, each item has a unique
empirically derived ‘weight’ from zero to 100 with
a score of 100 indicating maximum disability.7
Arterial blood gas
ABG analysis of the cases was performed by Roche
OMNI C BG/ISE device.
Sputum processing and analysis
Four slides were prepared from the sputum
samples, where two of them stained with hematox-
ylin-eosin, and the other two with giemsa. The
criteria for the adequacy of the material were the
presence of alveolar macrophages or respiratory
epithelial cells. Single-blind pathologic evaluation
was performed under light microscopy. The density
of inflammation was divided into four categories
(+1, +2, +3, +4) subjectively. Then, 10 high power
fields where the inflammatory cells are most dense
were evaluated to determine the percentages of
neutrophils and eosinophils.
Subjects gave informed consent agreement for
their participation in this trial. The study protocol
was approved by the Hospital Ethics Committee.
Statistical analysis
The SPSS program (SPSS, 10,0 Inc, Chicago, IL, USA)
was used to analyze the data. The arithmetic mean
and standard deviation were calculated for all
variables. For the analysis of COPD severity with
other parameters (gender, occupation, smoking
status, treatment modality, exacerbations in a lastTable 1 Demographic and physiological findings of two
LTA (+) (n:5
Gender (M/F) 52/6
Age (year) 64.570.8
Duration of disease (year) 8.475.7
Exacerbation number (per year) 0.770.9
Smoking history (pack year) 51.5731.7
Co-morbidity () (%) 34.5
FVC (lt) 2.570.8
FEV1 (lt) 1.470.5
FEV1/FVC 55.0711.3
PEF (%) 41.5718.7
*w2-test.
**Student’s t-test.year, comorbidity, and physical examination fin-
dings), w2-test was used. Comparison of the
montelukast group and control group according to
PFT, VAS and SGRQ scores was done by t-test.
Comparison of percent changes in montelukast
group and control group was done by Student’s t-
test. Fisher’s exact test was used for the compar-
ison of neutrophilic content of sputum between two
groups. Po0:05 was accepted as an statistically
meaningful.Results
One hundred and seventeen patients (100 male, 17
female) with median age 65.7279.11 (44–84)
participated in the study. There was no significant
difference between the two groups about age,
smoking status, duration of disease, ABG, PFT,
VAS, and SGRQ scores (symptom, impact, activity,
and total) at the beginning of the study
(P40:05)(Table 1).
At the end of the second month, a significant
improvement had been obtained in the pulmonary
function parameters (FEV1, FVC, FEV1/FVC, PEF) of
the montelukast group (Po0:05) (Fig. 1). FEV1,
FVC(%), FEV1/FVC and PEF values were increased to
1.5470.48 l+(95% confidence interval (CI)
1.48–1.72), 73.9712.6 (95% CI 69.88–76.50),
61.376.8 (95% CI 59.47–63.07), 45.8718.4 (95%
CI 40.96–50.65), respectively. There was not any
significant change in the parameters above of the
other group (P40:05).
The QoL and VAS scores also significantly im-
proved in the montelukast group at the end of
second month (Po0:05) (Figs. 2 and 3). The basal
symptom, impact, activity and total QoL scores of
the montelukast group were 49712.8 (95% CIgroups.
8) LTA () (n:59) P
48/11 40.05*
66.970.9 40.05**
7.575.2 40.05**
0.871.0 40.05*
51.2737.9 40.05**
42.4 o0.05*
2.670.7 40.05**
1.370.4 40.05**
51.5711.4 40.05**
30.5717.5 40.05**
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Figure 2 Comparison of (A) symptom, (B) impact, (C)
activity, and (D) total scores of SGRQ in LTA (+) and LTA
() groups.
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Figure 1 Comparison of (A) FEV1(lt), (B) FVC (lt), (C)
FEV1/FVC, (D) PEF (% predicted) in LTA (+) and LTA()
groups.
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Figure 3 Comparison of VAS results in LTA (+) and LTA ()
groups.
Short-term effects of montelukast 44745.63–52.35), 35.5717.9 (95% CI 30.75–40.16),
54.9718.5 (95% CI 50.03–59.78), and 43.3716.1
(95% CI 39.04–47.50) and at the end of the second
month they were all improved to 42.8713.0 (95%
CI 39.41–46.25), 23.7713.4 (95% CI 20.10–27.16),
38.4713.6(95% CI 34.83–41.99), and 30.9712.6
(95% CI 27.62–34.24), respectively. Basal VAS scores
65.2710.0mm (95% CI 59.68–72.4) were also
improved at the end of the study 47.7715.2mm
(95% CI 41.2–53.2). No significant changes were
seen in the other group’s QoL and VAS scores
(Po0:05).
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Table 2 Comparison of percent change between LTA (+) and LTA () groups.
LTA (+) mean7SD** LTA () mean7SD** P
FVC 0.0970.23 0.0570.21 o0.05*
FEV1 0.1770.16 0.0270.12 o0.05*
FEV1/FVC 0.1670.26 0.1270.25 =0.05
*
PEF 0.2270.49 0.3470.49 40.05*
Symptom score 0.1170.17 0.170.22 o0.05*
Impact score 0.2670.37 0.0570.25 o0.05*
Activity score 0.2570.26 0.1771.18 o0.05*
Total score 0.2570.23 0.0470.17 o0.05*
VAS 0.570.37 0.0670.11 o0.05*
*Student’s t-test.
**[(Second monthbasal)Cbasal].
Table 3 Change in neutrophilic inflammation.
Neutrophilic percentage LTA(+)(n) LTA()(n)
Decreased 6 1
Increased 3 5
No change 4 5
Total 13 11
(Fisher’s exact test P ¼ 0:059).
P. Celik et al.448The comparisons of the percent changes of the
two groups had shown significant differences in all
parameters except PEF (Po0:05) (Table 2).
At the end of the study, there was a significant
difference of PaO2 in the montelukast group but
there was no difference between the two groups of
other ABG parameters.
None of the patients had exacerbations during
the study period.
Also, during the study, sputum samples were
obtained. 44 (37.6%) patients had sputum sample
but 24 (20.5%) patients’ sputum were evaluated (13
in montelukast group, 11 in control group). Change
in neutrophilic percentage before and after the
study was seen in Table 3. Since the percentages of
eosinophils were very low (2–3%), statistical ana-
lyses were not performed.Discussion
The pathophysiology of airway obstruction in COPD
is multifactorial, and involves neutrophilic airway
inflammation,2 protease–antiprotease imbalance,8
oxidative stress,9 T-cell predominant interstitial
inflammation,10 and recurrent infection.11 Analyses
of bronchial biopsies, resected lung tissue, and
induced sputum have shown that there is inflam-
mation, even in the stable phase of COPD. These
inflammatory processes in COPD are the reason for
the use of anti-inflammatory therapy in COPD.
Based on the effectiveness of inhaled corticos-
teroids as anti-inflammatory agents in the treat-
ment of asthma, the presence of mucosal
inflammation in COPD is one rationale for their
use in this condition. While the EUROSCOP and
ISOLDE clinical trials have shown no beneficial
effect of inhaled corticosteroids on the long termrate of lung function decline in COPD, they have
shown significant improvement in FEV1 over the
first 3–6 months of treatment.12,13
The non-cysteinyl leukotriene, LTB4 activates the
B leukotriene receptor, while the cysteinyl leuko-
trienes (leukotriene C4, leukotriene D4, leukotriene
E4) activate cysteinyl leukotriene receptors 1 and 2
subtypes. A single class of receptors in human
airway smooth muscle appears to mediate contrac-
tions induced by leukotriene C4, leukotriene D4,
and leukotriene E4. Although the most widely
recognized of effects of leukotrienes is broncho-
constriction, leukotrienes also induce mucus secre-
tion, inflammatory cell infiltration, microvascular
permeability, airway smooth muscle proliferation,
and neuronal input interactions.
Leukotriene receptor antagonists (such as mon-
telukast, zafirlukast, etc.) inhibit leukotriene C4
and leukotriene D4 induced contractions in isolated
airways,14 decrease leukotriene D4 and leukotriene
E4 induced microvascular permability,
15 slow down
the proliferation of airway smooth muscle,16 and
have potential to decrease mucus production and
increase mucus clearance.17
The first reported study about the use of LTA in
COPD is the one of Cazzola in which they found a
significant increase in FEV1 of a small number of
stable moderate to severe COPD patients after
giving zafirlukast non-consecutively for 2 or 4 days.
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particular bronchodilator effects in partially rever-
sible COPD cases but added the lack of this effect
on fixed airway obstruction.18,19 In another study
concerning the short-term (within 2 h) efficacy of
LTA, zafirlukast, in COPD patients with severe
airway obstruction, anti-bronchoconstrictive or
bronchodilator effect has been shown.20
LTA montelukast’s efficacy has been investigated
in rats exposed to cigarette smoke and it has been
found that leukotrienes can play a role in the
pathogenesis of smoking-related lung diseases, and
that montelukast may inhibit lung injury due to
active and passive to cigarette smoking.21 In a long-
term (2 years) retrospective study, Rubenstein
showed a significant improvement in COPD control
without any change in functional parameters in old,
moderate to severe COPD patients.22
In this study, we have investigated the short-term
efficacy of LTA in stable patients with moderate to
severe COPD, the two groups with or without LTA
were compared according to PFT parameters,
dyspnea scores, health-related QoL scores, ABG,
and sputum neutrophil content. There was a
significant increase in respiratory function para-
meters (FVC, FEV1, FEV1/FVC and PEF) in the group
with LTA (Po0:05).
SGRQ is one of the best detailed and standardized
questionnaires in COPD. It consists of three parts as
symptoms, impact and activity. When two groups in
the study were compared in terms of these physical,
pschycological and social parameters, the group
with LTA had a decrease in all three scales of
symptom, impact and activity (Po0:05).
Dyspnea is the most frequently seen and com-
plained symptom in COPD patients. This symptom is
chronic, progressive, and deteriorates with disease
progression. A good correlation between the scales
used in the evaluation of dyspnea such as Medical
Research Council (MRC), Baseline Dyspnea Index
(BDI) and FEV1 has been reported.
23 We used VAS in
dyspnea evaluation and found a decrease in both
groups but it was more significant in montelukast
group (Po0:05).
Airway inflammation in COPD can be demons-
trated by the examination of sputum. Smokers and
exsmokers with COPD have increased sputum
neutrophil numbers compared with subjects with-
out COPD,24 and increased neutrophils are asso-
ciated with rapid decline in FEV1.
2 Furthermore,
the neutrophil activation markers, myeloperoxi-
dase and lactoferrin, are elevated in the sputum of
COPD subjects,25 indicating that neutrophils are
active participants in airway inflammation. We
could have done sputum analysis and evaluated
the neutrophilic inflammation in 24 of the cases;the percent of neutrophils decreased by the
treatment in montelukast group but this was not
statistically significant as it was in the other clinical
improvements obtained, probably due to the small
number of patients (P ¼ 0:059).
Seventeen COPD patients had the leukotriene
synthesis inhibitor BAY X1005 orally for 14 days and
LTB4, myeloperoxidase and chemotactic activity
were investigated in spontaneous sputum samples.
There were no significant changes in the para-
meters mentioned above except for a decrease in
LTB4 concentrations and the authors concluded that
leukotriene synthesis inhibitors have caused a mild
decrease in neutrophilic bronchial inflammation in
COPD cases.26 It is clear that further studies
including biochemical and molecular investigations
on that aspect are needed.
The present study has many limitations; the
impact of adding an LTA to routine protocols had
been investigated but the solitary effect of inhaled
corticosteroids had not been evaluated and the
comparison of these two drugs had not been made.
As far as we have seen, of these improvements with
LTA, it would be worth of studying these aspects in
further studies. The second limitation is the
duration of the study in which we had evaluated
the short-term effects but long-term outcomes
such as emergency visit, the number and the
duration of exacerbations could give different
results. The improvements obtained in subjective
parameters such as VAS and QoL and in the
objective parameters such as functional tests had
not been obtained in the inflammatory markers in
sputum due to the small number of cases.
Despite the limitations mentioned above, the
results of this particular study had been encoura-
ging for the planning of further studies with LTA in
COPD patients.
In conclusion, this study with montelukast in
stable patients with moderate to severe COPD
showed a significant improvement in respiratory
functions, dyspnea scores, QOL Scores, and a non-
significant improvement in sputum neutrophilia in
the short term. The results of such studies showing
improvements with anti-inflammatory treatment in
COPD might make physicians consider these com-
plementary drugs. Long-term, placebo-controlled
studies with these drugs might make an impact on
that aspect.References
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